在关键的ACHIEVE-3临床试验中，礼来公司研发的Orforglipron（36毫克剂量）展现出显著优势。针对主要疗效终点——糖化血红蛋白（A1c）的降低幅度，数据显示：Orforglipron治疗组实现了2.2%的A1c下降，而对照药物口服司美格鲁肽（14毫克剂量）组的降幅为1.4%。这一结果凸显了Orforglipron在血糖控制方面的潜在卓越疗效。
在关键的ACHIEVE-3临床试验中，礼来公司研发的Orforglipron（36毫克剂量）展现出显著优势。针对主要疗效终点——糖化血红蛋白（A1c）的降低幅度，数据显示：Orforglipron治疗组实现了2.2%的A1c下降，而对照药物口服司美格鲁肽（14毫克剂量）组的降幅为1.4%。这一结果凸显了Orforglipron在血糖控制方面的潜在卓越疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.